
BMS and Gritstone enter solid tumor trial collaboration
Executive Summary
Bristol-Myers Squibb Co. and Gritstone Oncology will together evaluate immunotherapy combinations for advanced solid tumors.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com